Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (ASPAIT)

STATUS

Recruiting
End date

Dec 21, 2025
participants needed

680
sponsor

First Affiliated Hospital, Sun Yat-Sen University

Send

Updated on 23 February 2022

See if I qualify

endocrine therapy

metastasis

hormone therapy

immunohistochemistry

tamoxifen

aromatase inhibitor

invasive breast cancer

adjuvant chemotherapy

immunostimulant

Summary

The objective of this study is to compare the curative effects in patients under the age of 35 with hormone receptor positive breast cancer and high recurrent risk factors including large tumor or metastatic lymph nodes randomized to ovarian function suppression (OFS) plus aromatase inhibitors or OFS plus tamoxifen as adjuvant endocrine therapy, and explore the differences of curative effects between different subtypes to provide direct evidence for treatments of young breast cancer patients.

Details

Condition	Breast Cancer
Treatment	Goserelin, tamoxifen, Aromatase Inhibitors
Clinical Study Identifier	NCT02914158
Sponsor	First Affiliated Hospital, Sun Yat-Sen University
Last Modified on	23 February 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Signed informed consent
	Eastern Cooperative Oncology Group (ECOG) performance status 2
	Patients pathologically diagnosed with hormone receptor positive invasive breast cancer: immunohistochemistry ER positive (1%)
	Premenopausal patients with age 35 years (at least menstruate once for prior 3 months, assess menstruation situation before chemotherapy if have)
	No distant metastasis
	Clinical stage (TNM) meets at least one of the conditions as follow: T2cm or at least one region of regional lymph node metastasis (including micrometastases)
	Patients must have undergone a surgery and (neo)adjuvant chemotherapy, targeted therapy, radiotherapy (if necessary) according to Chinese Anti-Cancer Association guidelines and specifications version 2015 for diagnosis and treatment of breast cancer
	Indexes of hematology and biochemistry conform to following standards: HGB10g/dl, WBC4,000/mm3, PLT100,000/mm3, GOT, GPT, ALP2xULN, TBIL, DBIL, CCr1.5xULN
Exclusion Criteria
	Pregnant or lactating women or women of childbearing potential reject contraceptive measures
	History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation)
	Concurrent malignancies or history of non-breast malignancies within the 5 years prior to study entry, except for curatively treated basal cell and squamous cell carcinomas of the skin, carcinoma in situ of the cervix; peripheral nervous system disorders caused by diseases or history of obvious mental and central nervous system disorders
	Prior use of neo-adjuvant chemotherapy after a definite diagnosis
	Nervous system disorders caused by diseases or obvious mental disorder, which would affect patients right to consent and compliance, or make patients in critical condition
	Serious hepatopathy (e.g., cirrhosis, etc.), nephropathy, respiratory illness, digestive illness or poorly controlled diabetes
	Cardiac illness with obvious abnormal EKG or clinical symptoms, namely congestive heart failure, coronary atherosclerotic heart disease with obvious symptoms, arrhythmia difficult to control by drugs, or history of myocardial infarction within the 12 months prior to study entry or class III/IV of cardiac function
	Concurrent treatment in another investigational trial
	Sensitivity or contraindication to any of the study medications

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

invasive breast cancer

adjuvant chemotherapy

immunostimulant

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (ASPAIT)